Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Magn Reson Imaging Clin N Am. 2008 Nov;16(4):697-710, ix-x. doi: 10.1016/j.mric.2008.07.005.

Advances in MR spectroscopy of the prostate.

Author information

  • 1University of California, San Francisco, San Francisco, CA 94158, USA. john.kurhanewicz@radiology.ucsf.edu

Abstract

Commercial MR imaging/magnetic resonance spectroscopic imaging (MRSI) packages for staging prostate cancer on 1.5-T MR scanners are now available. The technology is becoming mature enough to begin assessing its clinical utility in selecting, planning, and following prostate cancer therapy. Before therapy, 1.5-T MR imaging/MRSI has the potential to improve the local evaluation of prostate cancer presence and volume and has a significant incremental benefit in the prediction of pathologic stage when added to clinical nomograms. After therapy, two metabolic biomarkers of effective and ineffective therapy have been identified and are being validated with 10-year outcomes. Accuracy can be improved by performing MR imaging/MRSI at higher magnetic field strengths, using more sensitive hyperpolarized (13)C MRSI techniques and through the addition of other functional MR techniques.

PMID:
18926432
[PubMed - indexed for MEDLINE]
PMCID:
PMC2774494
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk